1. Scrip
  2. >>Business
  3. >>Strategy

Spain’s Grifols Takes Restructuring Route After COVID Challenges

Over 2,000 Jobs To Go In US

 
• By Kevin Grogan

The Barcelona-based company is making major cuts to its headcount in a bid to save €400m and support its operational recovery after the significant impact of the pandemic to Grifol’s plasma business.

severing ties and boycott concept
• Source: Shutterstock

Grifols, S.A. is the latest biopharma company forced to cut its cloth to suit the straitened times the sector is suffering, with the Spanish plasma powerhouse unveiling plans to axe 8% of its workforce, with the US taking the brunt.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

More from Business